The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1672
March 20, 2023
View Complete Issue         Table of Contents 2019 
A Dexamethasone Ophthalmic Insert (Dextenza) for Allergic Conjunctivitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Dexamethasone Ophthalmic Insert (Dextenza) for Allergic Conjunctivitis
March 20, 2023 (Issue: 1672)
The FDA has approved Dextenza (Ocular Therapeutix), a dexamethasone ophthalmic insert, for treatment of ocular itching associated with allergic conjunctivitis. Dextenza was approved earlier for treatment of ocular inflammation and pain...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Dexamethasone Ophthalmic Insert (Dextenza) for Allergic Conjunctivitis
Article code: 1672b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.